Janssen announced the submission of supplemental New Drug Applications (sNDAs) to the FDA for Invega Sustenna (paliperidone palmitate), an atypical long-acting antipsychotic for the treatment of schizoaffective disorder as either monotherapy or adjunctive therapy.
The submissions were based on a 15-month study that found Invega Sustenna met its primary endpoint of delayed time to and reduced risk of relapse compared to placebo. It also demonstrated significant efficacy in manic and depressive mood symptoms and psychosis.
Invega Sustenna is already approved for the acute and maintenance treatment of schizophrenia.
For more information call (800) 526-7736 or visit InvegaSustenna.com.